Filter posts

The Administration’s Orwellian Defense of Importing Foreign Price Controls

The Trump administration is out with a new blog post defending its plan to adopt …

Think the Drug-Pricing debate addresses Patient Costs? Think again.

Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate …

Patient Advocates Sounding the Alarm Over Fail First

The Centers for Medicare & Medicaid Services (CMS) has reversed a long-standing policy allowing Medicare …

Watchdog Report Reaffirms Concerns With Fail First

A new report by the Office of Inspector General at the U.S. Department of Health …

Hits to Patients Keep on Coming

At a time when prescription drug prices and spending are remarkably stable, patients are getting …

On the President’s Drug Cost Plan, Three Important Concerns

Part 2. Upending Access in Medicare Part B program This week, BIO launched a three-part …

Cancer Docs Weigh in on Medicare Part B Demo

This week, American Society of Clinical Oncology (ASCO) President Daniel Hayes, MD and CEO Clifford …

What They’re Saying about the Medicare Part B Demo

Back in March, CMS’s Center for Medicare and Medicaid Innovation (CMMI) proposed a sweeping demonstration …

Morning Consult: Medicare’s Deadly Cancer Care Gamble

Today in Morning Consult, cancer survivor and health economist Jennifer Hinkel writes about the threat …

Immune Deficiency Foundation: Medicare’s “one size fits all” drug demo is wrong for seniors wi...

Writing yesterday in The Hill, Immune Deficiency Foundation President Marcia Boyle explains the potential harm posed …